Literature DB >> 25029939

Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy.

Matthias Blaickner1, Richard P Baum2.   

Abstract

Personalized dosimetry in radionuclide therapy has gained much attention in recent years. This attention has also an impact on peptide receptor radionuclide therapy (PRRT). This article reviews the PET-based imaging techniques that can be used for pretherapeutic prediction of doses in PRRT. More specifically the usage of (86)Y, (90)Y, (68)Ga, and (44)Sc are discussed: their characteristics for PET acquisition, the available peptides for labeling, the specifics of the imaging protocols, and the experiences gained from phantom and clinical studies. These techniques are evaluated with regard to their usefulness for dosimetry predictions in PRRT, and future perspectives are discussed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Keywords:  Correlation with clinical response; Dosimetry; PET/CT; Peptide receptor radionuclide therapy; Planar imaging; Pretherapeutic treatment planning; Radiobiological models; SPECT/CT

Mesh:

Substances:

Year:  2013        PMID: 25029939     DOI: 10.1016/j.cpet.2013.08.014

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  3 in total

1.  Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Benedikt Feuerecker; Maythinee Chantadisai; Anne Allmann; Robert Tauber; Jakob Allmann; Lisa Steinhelfer; Isabel Rauscher; Alexander Wurzer; Hans-Jürgen Wester; Wolfgang A Weber; Calogero d'Alessandria; Matthias Eiber
Journal:  J Nucl Med       Date:  2021-09-16       Impact factor: 11.082

2.  Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Authors:  L Bodei; M Kidd; I M Modlin; S Severi; I Drozdov; S Nicolini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

3.  PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Jaroslaw Cwikla; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-26       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.